ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 8, 2020

SEC Form 3/A — Form 3/A

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Powell Andrew Kenneth William (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$10.25	2030-11-04	Common Stock (52053)		Direct

Footnotes

F1: The Shares shall vest in 36 equal monthly installments beginning on November 9, 2020.

F2: These shares were omitted from the reporting person's original Form 3.